We divided 54 samples from 78 AML patients into the CD69+CD34+CD38− group and the CD69−CD34+CD38− group based on the expression level of CD69 (See “Material and methods”; Additional file 1: Fig. S5e) [30]. This evidence concerns the gene CD38 and acute myeloid leukemia.